@article {Ruiz-Irastorza2020.07.16.20152868, author = {Guillermo Ruiz-Irastorza and Jose-Ignacio Pijoan and Elena Bereciartua and Susanna Dunder and Jokin Dominguez and Paula Garcia-Escudero and Alejandro Rodrigo and Carlota Gomez-Carballo and Jimena Varona and Laura Guio and Marta Ibarrola and Amaia Ugarte and Agustin Martinez-Berriotxoa and On behalf of the Cruces COVID Study Group}, title = {Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data}, elocation-id = {2020.07.16.20152868}, year = {2020}, doi = {10.1101/2020.07.16.20152868}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {OBJECTIVE To analyze the effects of a short course of methyl-prednisolone pulses (MP) during the second week of disease (week-2) on the clinical course of patients with severe coronavirus disease 2019 (COVID-19) pneumonia.DESIGN Comparative observational study using data collected from routine care.SETTING Hospital Universitario Cruces, a tertiary level University hospital at Barakaldo, Bizkaia, Spain.PARTICIPANTS All patients with COVID-19 pneumonia admitted between 1st March and 30th April 2020 to the services of Infectious Diseases and Internal Medicine.INTERVENTIONS Treatment with week-2-MP (125-250 mg/d for 3 consecutive days with no subsequent tapering) vs. standard of care.MAIN OUTCOMES MEASURES Time to death and time to death or endotracheal intubation.RESULTS Two hundred and forty-two patients with confirmed COVID-19 pneumonia and elevated inflammatory markers at admission were included in the study. Sixty-one patients (25\%) received week-2-MP. Twenty-two patients (9\%) died during the study period. Thirty-one patients (12.8\%) suffered death or intubation. The adjusted HR for death was 0.35 (95\%CI 0.11 to 1.06, p= 0.064) for patients in the week-2-MP group. The adjusted HR for death or intubation week-2-MP was 0.33 (95\%CI 0.13 to 0.84, p=0.020) for patients in the week-2-MP group. These differences were seen in the subcohort of patients with a SaO2/FiO2 at day 7 lower than the median of the whole population: HR 0.31, 95\% CI 0.08 to 1.12, p=0.073 and HR 0.34, 95\%CI 0.12 to 0.94, p=0.038, respectively, but not in patients with higher SaO2/FiO2. Other predictors of the final outcomes were arterial hypertension, SaO2/FiO2, high-risk CURB65 scores and the use of non-pulse glucocorticoids. Non-pulse glucocorticoids were a predictor of infections (OR 4.72, 95\%CI 1.90 to 11.80, p\<0.001), while week-2-MP were not (OR 1.04, 95\%CI 0.40 to 2.70, p=0.938).CONCLUSIONS Week-2-MP are effective in improving the prognosis of patients with COVID-19 pneumonia with features of inflammatory activity and respiratory deterioration entering the second week of disease. The recognition of this high-risk population should prompt early use of MP at this point.REGISTRATION This study has been registered in the EU PAS Register with the number EUPAS36287.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEUPAS36287Funding StatementThe was no external funding for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Basque Country Research Ethics Committee (code EPA2020032).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original data would be available upon request.}, URL = {https://www.medrxiv.org/content/early/2020/07/23/2020.07.16.20152868}, eprint = {https://www.medrxiv.org/content/early/2020/07/23/2020.07.16.20152868.full.pdf}, journal = {medRxiv} }